Wednesday, September 26, 2018
 
 
Company News: Page (1) of 1 - 04/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality
If approved by the FDA, esketamine nasal spray would be the first medication for treatment of patients with major depressive disorder at imminent risk for suicide
(April 16, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:USA,Medicine,Disease,Therapy,Surgery,Medication,Science,Lifestyle,Medical,Science,Adults,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines